Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
820.10
-6.31 (-0.76%)
At close: Oct 28, 2025, 4:00 PM EDT
818.01
-2.09 (-0.25%)
After-hours: Oct 28, 2025, 7:18 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $15.56B in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
13.96
Revenue / Employee
$1,133,151
Employees
47,000
Market Cap
736.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Novo Nordisk | 49.11B |
| Abbott Laboratories | 43.84B |
LLY News
- 4 hours ago - Lilly partners with Nvidia on AI supercomputer to speed up drug development - Reuters
- 4 hours ago - Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development - CNBC
- 4 hours ago - Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients - PRNewsWire
- 4 hours ago - Eli Lilly Partners With Nvidia to Build AI Supercomputer for Drug Discovery - WSJ
- 8 hours ago - Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings - CNBC
- 1 day ago - Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis - PRNewsWire
- 1 day ago - Lilly declares fourth-quarter 2025 dividend - PRNewsWire
- 1 day ago - Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha